Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) had its price objective lowered by HC Wainwright from $14.00 to $11.00 ...

Advancements in precision medicine drive the 5-HT2 agonist market by enabling selective targeting of specific receptor subtypes (e.g., 5-HT2A or 5-HT2C), reducing side effects and improving safety.

Reviva Pharmaceuticals Holdings Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of 90.48%. The profit margin, also known as the revenue ratio or gross ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insmed (INSM – Research Report) and Reviva ...

H.C. Wainwright lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $11 from $14 and keeps a Buy rating on the shares. Johnson ...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) saw some unusual options trading on Tuesday. Investors acquired 13,196 call options on the stock. This represents an increase of ...

In recent trading, Reviva Pharmaceuticals Holdings Inc (RVPH) stock price has shown some volatility, fluctuating -19.80% over the last ...

Featured here, the Balance Sheet for Reviva Pharmaceuticals Holdings, Inc., which summarises the company's financial position including assets, liabilities and shareholder equity for each of the ...

Fintel reports that on January 10, 2025, Maxim Group upgraded their outlook for Reviva Pharmaceuticals Holdings (NasdaqCM:RVPH) from Hold to Buy. Analyst Price Forecast Suggests 724.68% Upside As ...

On Friday, Maxim (NASDAQ:MXIM) Group analyst Jason McCarthy upgraded Reviva Pharmaceuticals Holdings Inc. (NASDAQ:RVPH) stock rating from Hold to Buy and established a new price target of $7.00, well ...